Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant

HIV-1-infection Clinical Trial

Official title:

Effect of CCR5 Inhibition by Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant for Any Indication and Its Observed Effect on Graft Versus Host Disease and HIV-1 Persistence

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03118661
• Other study ID #: 201704019
• Status: Withdrawn
• Phase: Phase 1
• Start date: March 19, 2018
• Est. completion date: September 30, 2025

Study information

• Verified date: November 2018
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this proposal is to determine the effect of maraviroc when it has been a part of the antiretroviral (ART) regimen given immediately after allogeneic hematopoietic cell transplant (allo-HCT) for HIV-1 infected participants who have a hematopoietic malignancy or other underlying disorder requiring an allogeneic transplant. Maraviroc has been given in practice to alleviate symptoms of graft vs. host disease (GvHD). Given its mechanism of action, it may also have an effect on the reservoir size of HIV-1 in infected patients. This study will inform potential future studies, evaluating the effect of this approach on the incidence and severity of GvHD, and determining its effect on HIV-1 reservoir.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 30, 2025
• Est. primary completion date: September 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria (Step 1)

• HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA VL.

• Receipt of allo-HCT for any indication at least 100 days prior to study entry.

• Receipt of maraviroc for at least 30 days starting at date of transplant. Longer receipt of maraviroc is acceptable. Documentation of HIV-1 tropism for CCR5 should be obtained if available, but it is not necessary that the participant have prior CCR5-tropic.

• At least 18 years of age.

• HIV-1 RNA that is <50 copies/mL using a FDA-approved assay performed by any laboratory that has a CLIA certification or its equivalent within 45 days prior to study entry.

• For females of reproductive potential (i.e., women who have not been post-menopausal for at least 24 consecutive months, who have had menses within the preceding 24 months, or women who have not undergone surgical sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral salpingectomy), negative urine pregnancy test (with a sensitivity of 15-25 mIU/mL) within 48 hours prior to screening and entry.

• Negative HBsAg result obtained within 6 months prior to study entry, or documentation of HBV immunity by positive HBV sAb at any time

• The following laboratory values obtained within 45 days prior to enrollment:

• CD4+ T cell count >250 cells/ mm^3

• Absolute neutrophil count (ANC) =1000 cells/mm^3

• Hemoglobin =10.0 g/dL for men and =9.0 g/dL for women

• Platelet count = 50,000/mm3

• Ability and willingness of participant or legal representative to provide informed consent.

Additional Inclusion Criteria for Step 2 of Study:

• HIV-1 latent reservoir undetectable by co-culture and DNA

• No confirmed detectable HIV-1 RNA > 1000 cells/mm3 since discontinuation of maraviroc

• Prior HIV-1 genotype results that confirm that there are active agents available in at least three classes of ART drugs (NRTI, NNRTI, PI or integrase).

• Willing to stop ART

• Willing to undergo high volume blood draw (125 cc) at Week 16

• Willing to restart ART if HIV-1 viremia returns

• Provide informed consent for Step 2

Exclusion Criteria:

• Ongoing AIDS-related opportunistic infection (including oral thrush).

• Pregnant and/or breastfeeding.

Related Conditions & MeSH terms

• HIV-1-infection

Intervention

Other:
• For Step 2: Structured treatment interruption
-Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection

Procedure:
• Peripheral blood draw
-Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HIV-1 proviral DNA levels in peripheral blood	Obtained from peripheral blood; Used to determine if participant can proceed to Step 2	Up to week 16 after transplant
Primary	HIV-1 reactivation in stimulated assay	Obtained from peripheral blood; Used to determine if participant can proceed to Step 2	Up to week 16 after transplant
Primary	Presence and severity of GvHD	-GvHD will be measured using the NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: IV. Response Criteria Working Group Report	Through 5 years after transplant
Primary	Time to hematopoietic cell and immune recovery	-In general, the mean time of engraftment of the donor cells is approximately 90 to 100 days post-transplant and this can be monitored by measuring the percent chimerism of donor cells.	Up to 100 days after transplant
Primary	Number of participants who experience chimerism	-Chimerism is measured by = 98% of blood cells donor derived	At the time of screening
Primary	Survival of participants	-Number of participants who are alive 100 days after transplant	100 days after transplant
Primary	Survival of participants	-Number of participants who are alive 26 weeks after transplant	Week 26 after transplant
Primary	Survival of participants	-Number of participants who are alive 52 weeks after transplant	Week 52 after transplant
Primary	Survival of participants	-Number of participants who are alive 5 years after transplant	5 years after transplant
Primary	Event free survival	-Defined as survival where the cancer does not recur, the graft takes, and there are no life-threatening events	100 days after transplant
Primary	Event free survival	-Defined as survival where the cancer does not recur, the graft takes, and there are no life-threatening events	Week 26 after transplant
Primary	Event free survival	-Defined as survival where the cancer does not recur, the graft takes, and there are no life-threatening events	Week 52 after transplant
Primary	Event free survival	-Defined as survival where the cancer does not recur, the graft takes, and there are no life-threatening events	5 years after transplant
Secondary	Number of participants who achieve a state of functional cure	-Functional Cure: Following the discontinuation of all HIV-1 related treatment interventions, including HAART, a participant will be considered to have achieved an HIV-1 functional cure if for at least 5 years they: maintain an undetectable plasma viral load, using standard clinical assays, have achieved full CD4+ lymphocyte recovery with normal levels of T cell activation and proliferation, and normal levels of immunoglobulins with no disease progression. It is anticipated that participants who have achieved a functional cure will continue to have detectable HIV-1 DNA in peripheral blood cells and/or tissues.	Through 5 years after transplant
Secondary	Number of participants who achieve a state of sterilizing cure	-Sterilizing cure: same definition of functional cure but no detectable replication-competent virus in peripheral blood and minimal (near limits of detection) HIV-1 DNA in peripheral blood and or tissue	Through 5 years after transplant
Secondary	Number of participants who have plasma viral load <50 copies/ml	-Obtained from peripheral blood	Through 5 years after transplant
Secondary	Number of participants who have existence of replication competent HIV-1 reservoirs in peripheral blood, gut and other tissue compartments	-Obtained from peripheral blood	Through 5 years after transplant
Secondary	Number of participants who have gut immune reconstitution	-Will consist of tissue immunohistochemistry to analyze CD4 T cells when feasible, and for plasma markers of gut microbial translocation namely lipopolysaccharide (LPS) and soluble CD14 (sCD14) a marker of monocyte activation attributed to LPS effects	Through 5 years after transplant

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine